C-1400-01 (AGEN1777) (Agenus, Inc.)
Description: A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients With Advanced Solid Tumors
Mechanism of Action: bispecific antibody targeting TIGIT and CD96 (to enhance T and NK cell activation)
Target Population: All solid tumors. To be given as single agent or in combination with Balstilimab
Study Design: Study drug is administered IV every 3 weeks.